Curious about AstraZeneca net worth in 2024? Here at Ando Money, I’m diving into AstraZeneca’s financial performance, focusing on its major revenue contributors like its Pharmaceuticals and Oncology divisions.
Let’s take a close look at what makes AstraZeneca a financial powerhouse.
Quick Facts
| FACT | DETAIL |
|---|---|
| Name | AstraZeneca |
| Full Name | AstraZeneca PLC |
| Industry | Pharmaceuticals |
| Traded as | LSE: AZN, NYSE: AZN, NASDAQ OMX: AZN |
| ISIN | GB0009895292 |
| Founded | 1999 |
| Founders | Astra AB, Zeneca Group PLC |
| Country/Territory | United Kingdom |
| Headquarters | Cambridge, England, UK |
| Chief Executive Officer | Pascal Soriot |
| Number of Employees | 83,000 |
| Market Cap | $241.92 Billion |
| Total Assets | $104,340 Million |
| Total Equity | $39,598 Million |
| Revenue | $25,617 Million (H1 2024) |
| Net Income | $4,108 Million (H1 2024) |
What is the Net Worth/Market Cap of AstraZeneca in 2024?
In 2024, AstraZeneca’s net worth or market cap stands at $241.92 billion. This makes it one of the key players in the pharmaceutical sector.
When comparing AstraZeneca’s financial power, it is on a similar level with other major pharmaceutical companies. Such notable peers include:
- Pfizer
- GlaxoSmithKline
- Amgen
- Daiichi Sankyo
- Alexion Pharmaceuticals
- Zeneca Group
- Astra AB
- Fusion Pharmaceuticals
- Cellectis
- Amolyt Pharma
If you’re curious about the wealthiest companies globally, feel free to check out our in-depth analysis of the most prosperous companies.
This comparison showcases how AstraZeneca holds its own amongst the industry’s giants.
Financial Performance Overview
Contributions from Pharmaceuticals and Oncology Division
AstraZeneca‘s Pharmaceuticals and Oncology division has been one of its largest contributors to revenue growth in 2024.
The Oncology segment, in particular, has seen impressive numbers, with a total revenue of $10,440 million in H1 2024, which is a 19% increase compared to last year.
The key products here include Tagrisso, which brought in $3,203 million, and Imfinzi with $2,259 million.
The growth in oncology was primarily driven by high global demand for medicines like Tagrisso, which has successfully gained momentum in adjuvant and first-line settings.
Moreover, Imfinzi has seen its demand grow significantly across various regions, especially in the US and Europe, showcasing AstraZeneca’s impact in the cancer treatment sector.
Calquence, another notable product, contributed $1,508 million, which is a 27% growth from H1 2023.
Cardiovascular, Renal, and Metabolism Contributions
Another significant revenue stream for AstraZeneca is its Cardiovascular, Renal, and Metabolism (CVRM) division. In the first half of 2024, CVRM contributed $6,220 million, representing an increase of 19%.
The leading contributor here was Farxiga, which generated $3,836 million in revenue, with growth attributed to its strong market positioning in heart failure and chronic kidney disease treatments.
Farxiga‘s growth is attributed to expanding use cases and favorable updates to treatment guidelines, boosting its presence in various markets, including US and Europe.
The success of Lokelma and roxadustat also strengthened the firm’s position in this segment, both showing consistent growth due to expanded access and new market entries.
Respiratory and Immunology Impact on Revenue
AstraZeneca’s Respiratory and Immunology (R&I) division posted a total revenue of $3,791 million for H1 2024, which marked an increase of 19%.
Major contributors were Symbicort, with a revenue of $1,491 million, and Fasenra, bringing in $781 million.
The growth within the R&I segment was driven by continued demand for Symbicort in major markets, particularly in emerging regions.
Meanwhile, Tezspire, a newer product, achieved notable success, contributing $280 million—its adoption rate and market entry into Japan and Europe significantly impacted its growth trajectory.
Rare Disease Portfolio’s Financial Contribution
AstraZeneca’s Rare Disease segment generated $4,243 million in revenue during the first half of 2024, contributing 17% to the company’s overall revenue. Ultomiris, a significant driver, saw a revenue of $1,804 million, marking a 32% growth.
The growth of Ultomiris can be linked to expanded geographical reach and increased indications, especially in neurology.
Another notable product, Soliris, brought in $1,439 million. However, there was a decline of 13%, largely driven by conversions of existing patients to Ultomiris.
AstraZeneca continues to make strides in expanding treatments for rare diseases, and this segment’s growth trajectory is expected to contribute significantly to the company’s future revenue.
Vaccines and Immune Therapies Division Revenue
The Vaccines and Immune Therapies (V&I) segment brought in $350 million during H1 2024, a 45% decrease from the previous year.
This decline was mainly due to reduced COVID-19 mAbs sales. However, Beyfortus showed notable growth with $80 million in revenue, highlighting AstraZeneca’s efforts in expanding its vaccine portfolio.
The collaboration with Sanofi for Beyfortus is expected to gain further traction in upcoming quarters, especially with expansion into new markets.
While the V&I division faced a tough year, it remains a vital part of the firm’s overall portfolio, and potential upcoming approvals could steer a rebound in revenue.
Revenue from Strategic Partnerships and Collaborations
AstraZeneca’s partnerships and collaborations have made substantial contributions to its financial success.
Collaborations with companies like Daiichi Sankyo and Amgen have particularly impacted the revenue streams positively.
Combined sales of Enhertu, recorded with Daiichi Sankyo, totaled $1,772 million for H1 2024, marking substantial growth.
These alliances not only bring financial benefits but also strengthen AstraZeneca’s R&D capabilities, enabling the company to continue innovating across multiple therapeutic areas.
Such collaborations have become a core part of the firm’s strategy to maintain competitiveness in the pharmaceutical sector.
Financial Growth through Recent Acquisitions
Acquisitions have played a pivotal role in shaping AstraZeneca’s financial landscape. In 2024, the firm completed acquisitions of Fusion Pharmaceuticals and Amolyt Pharma.
The purchase of Fusion Pharmaceuticals adds innovative radioconjugates to the oncology portfolio, promising to contribute to future revenue.
Similarly, Amolyt Pharma‘s acquisition enhances AstraZeneca’s offering in rare diseases, expanding its market footprint.
These acquisitions are aligned with AstraZeneca’s long-term growth ambitions, aimed at delivering an $80 billion total revenue by 2030.
Regional Revenue Breakdown
AstraZeneca’s revenue by geography provides insights into its market distribution.
The US remained the largest contributor, with $10,695 million in H1 2024, a growth of 18%. The Emerging Markets, including China, contributed $7,119 million, showing strong growth driven by increased patient access and reimbursement coverage.
Europe also made substantial contributions, with a revenue of $5,365 million, increasing 23% from the previous year.
Growth in the European market was led by strong sales of oncology and respiratory products. AstraZeneca’s diverse market reach ensures a balanced contribution across different regions, mitigating risks and leveraging opportunities globally.
Revenue Generated by Other Medicines
AstraZeneca’s revenue from Other Medicines reached $573 million for H1 2024.
Although this was a 9% decrease, it still plays a role in contributing to the overall revenue.
Products such as Nexium continued to be important revenue sources despite facing competitive pressures and generic erosion.
The company’s strategic decision to focus on its core products and high-growth areas means that other non-core medicines provide consistent, though less significant, financial contributions.
FAQs About AstraZeneca
How has AstraZeneca’s Oncology division contributed to its revenue?
AstraZeneca’s Oncology division contributed $10,440 million in H1 2024, primarily driven by high sales of Tagrisso, Imfinzi, and Calquence.
What is AstraZeneca’s revenue from its Cardiovascular, Renal, and Metabolism division?
The CVRM division contributed $6,220 million in H1 2024, with Farxiga being the leading product in this category.
Which products drove AstraZeneca’s Respiratory and Immunology division?
Key contributors in the R&I division included Symbicort and Fasenra, with Tezspire gaining traction in new markets, contributing $3,791 million.
What is the role of acquisitions in AstraZeneca’s growth strategy?
Acquisitions like Fusion Pharmaceuticals and Amolyt Pharma have expanded AstraZeneca’s portfolio, contributing significantly to its financial growth in 2024.
How is AstraZeneca performing in its major regional markets?
The US was the largest market with $10,695 million, followed by Emerging Markets and Europe, which contributed $7,119 million and $5,365 million respectively.
Conclusion
I hope this detailed analysis provides a clearer picture of AstraZeneca’s financial performance in 2024.
If you have thoughts or questions, feel free to leave a comment or share. Visit Ando Money for more insights!
